The short version of ghrelin receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-01. Anything still debated is marked as such rather than presented as settled.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
Cellular thermal shift assay (CETSA) and proteome integral solubility alteration (PISA)-based proteomics are widely used in drug discovery as label-free, mass spectrometry–compatible methods for quantifying cellular target engagement (confirming that a drug binds its intended target), deconvoluting drug targets (identifying the protein target of compounds with unknown targets), and profiling off-target interactions at the proteome scale. CETSA measures drug-induced changes in protein thermal stability in intact cells or tissues and, when combined with proteomics, enables the unbiased identification and ranking of on- and off-targets, as well as supporting phenotypic hit mechanism-of-action studies. PISA extends thermal-shift principles by integrating protein solubility changes across a temperature gradient, substantially increasing throughput and enabling multiplexed analysis of multiple compounds, concentrations, or time points. This approach facilitates high-content target deconvolution and comparative mechanism-of-action profiling, including applications in low-input or automated workflows.
== A == ABO blood group system – abscisic acid – absorption spectrum – abyssal zone – acetylcholine – acetyl-CoA – acid – acid precipitation – acoelomate – acrosome – actin – action potential – active site – adaptive radiation – address-message concept – adenosine 5'-triphosphate – adenylyl cyclase – adrenal gland – adrenodoxin – aerobic organism – age structure – agonist – AIDS – albumin – aldehydes – aldosterone – algae – allantois – allele – allometry – allopatric speciation – allosteric binding site – allosteric effector – allosteric enzyme – allosteric site – allozyme – alpha helix – amino acid – aminoacyl tRNA synthetase – amino group – amniocentesis – amniote – amphipathic molecule – anabolism – anaerobic organism – anaerobic respiration – androgen – anemia – aneuploidy – angiosperm – anther – anthrax – antibiotic – antibody – anticodon – antidiuretic hormone – antigen – apical dominance – apical meristem – apolipoprotein – apoplast – apoptosis – aquaporin – Archaea – archegonium – arteriosclerosis – artery – arthritis – ascus – asexual reproduction – atomic number – ATP – ATP synthase – atrioventricular valve – atrium – autoimmune disease – autonomic nervous system – autosome – auxin – axillary bud – axon
Back pressure (or backpressure) is the term for a resistance to the desired flow of fluid through pipes. Obstructions or tight bends create backpressure via friction loss and pressure drop. In distributed systems in particular event-driven architecture, back pressure is a technique to regulate flow of data, ensuring that components do not become overwhelmed.
== Research == Compared to the disease burden of migraine, the amount of healthy life years lost, the field is severely underfunded. In the US in 2019, migraine research got just 7.8% of the funding expected based on its burden. In Europe, it was the most underfunded brain disease when compared to its economic impact.
is the net fluid movement between compartments. By convention, outward force is defined as positive, and inward force is defined as negative. The solution to the equation is known as the net filtration or net fluid movement (Jv). If positive, fluid will tend to leave the capillary (filtration). If negative, fluid will tend to enter the capillary (absorption). This equation has a number of important physiologic implications, especially when pathologic processes grossly alter one or more of the variables. According to Starling's equation, the movement of fluid depends on six variables:
Sources: en.wikipedia.org
== Alternative barcodes to DNA == DNA barcodes can have limitations. Many standard chemical reactions can degrade DNA and thus compromise the chemical barcodes, necessitating changing chemical reaction conditions that could alter the binding ability of the small molecule to its target. Additionally, the DNA tag is typically over 50 times larger than the molecule itself, potentially restricting the binding ability of each library member and sometimes interacting with the target itself, creating false hits or obscuring potentially otherwise strong binders. This is especially problematic when the target has nucleic acid binding sites, like transcription factors or RNA-binding proteins. For this reason, a multitude of barcode alternatives have been developed in efforts to mitigate these issues such as abiotic peptides, peptide nucleic acids, and even barcode free self-encoded libraries.
=== Other interactions === SSRIs, including citalopram, can increase the risk of bleeding, especially when coupled with aspirin, NSAIDs, warfarin, or other anticoagulants. Taking citalopram with omeprazole may cause higher blood levels of citalopram. This is a potentially dangerous interaction, so dosage adjustments may be needed or alternatives may be prescribed.
== Adverse effects == During clinical trials, the most common adverse effects of trastuzumab emtansine were fatigue, nausea, musculoskeletal pain, thrombocytopenia (low platelet counts), headache, increased liver enzyme levels, and constipation. Severe adverse events identified during the EMILIA trial included hepatotoxicity (liver damage), including rare cases of liver failure, hepatic encephalopathy, and nodular regenerative hyperplasia; heart damage (dysfunction of the left ventricle); interstitial lung disease, including acute interstitial pneumonitis; thrombocytopenia; and peripheral neuropathy. Overall, trastuzumab emtansine was better tolerated than the control treatment, a combination of lapatinib (Tykerb) and capecitabine (Xeloda), with 43% of patients in the trastuzumab emtansine group experiencing severe toxic effects, versus 59% of those who received lapatinib/capecitabine; furthermore, fewer patients had to stop treatment due to adverse effects than with lapatinib or capecitabine. Anemia, low platelet counts, and peripheral neuropathy were more common among patients who received trastuzumab emtansine, whereas heart damage and gastrointestinal effects, such as vomiting, diarrhea, and stomatitis, were more common with lapatinib/capecitabine. In the United States, trastuzumab emtansine carries black box warnings for liver toxicity, heart damage (reduction in left ventricular ejection fraction), and fetal harm if given to pregnant women.
==== Antibiotic Awareness Week ==== The World Health Organization has promoted the first World Antibiotic Awareness Week running from 16 to 22 November 2015. The aim of the week is to increase global awareness of antibiotic resistance. It also wants to promote the correct usage of antibiotics across all fields to prevent further instances of antibiotic resistance. World Antibiotic Awareness Week has been held every November since 2015. For 2017, the Food and Agriculture Organization of the United Nations (FAO), the World Health Organization (WHO) and the World Organisation for Animal Health (OIE) are together calling for responsible use of antibiotics in humans and animals to reduce the emergence of antibiotic resistance. United Nations In 2016, the Secretary-General of the United Nations convened the Interagency Coordination Group (IACG) on Antimicrobial Resistance. The IACG worked with international organizations and experts in human, animal, and plant health to create a plan to fight antimicrobial resistance. Their report released in April 2019 focuses on the seriousness of antimicrobial resistance and the threat it poses to world health. It suggests five recommendations for member states to follow to tackle this increasing threat. The IACG recommendations are as follows:
== Awards == Advance for Medical Laboratory Professionals received the Corporate Recognition Award from the Pennsylvania chapter of the American Society for Clinical Laboratory Science. In 2006, the trade journal's editor, Matthew Patton, won an award in the Awards for Publication Excellence in the Editorial and Advocacy Writing category
Sources: en.wikipedia.org
== External links == ADAM (A Database of Anti-Microbial peptides) Archived 2015-06-17 at the Wayback Machine at ntou.edu.tw AntiFP Prediction of antifungal peptides AntiMPmod Prediction of antimicrobial potential of modified peptides Antimicrobial+Cationic+Peptides at the U.S. National Library of Medicine Medical Subject Headings (MeSH) AntiTbPred Prediction of anti-tuberculosis peptides Antimicrobial Peptide Database Archived 2011-07-20 at the Wayback Machine at University of Nebraska Medical Center Antimicrobial Peptide Scanner Deep Learning based AMP prediction server AntiTbPdb Anti Tubercular Peptide Database BioPD[link removed] at Peking University Health Science Center CAMP:Collection of Anti-Microbial Peptides at National Institute for Research in Reproductive Health (NIRRH) DBAASP - Database of Antimicrobial Activity and Structure of Peptides] LAMP at Fudan University PeptideLocator Prediction of functional peptides, including antimicrobial peptides, in a protein sequence PeptideRanker Bioactive peptide, including antimicrobial peptide, prediction modlAMP Python package for computational work with antimicrobial peptides, including sequence handling, -design, -prediction, descriptor calculation and plotting
The best-known role of proteins in the cell is as enzymes, which catalyse chemical reactions. Enzymes are usually highly specific and accelerate only one or a few chemical reactions. Enzymes carry out most of the reactions involved in metabolism, as well as manipulating DNA in processes such as DNA replication, DNA repair, and transcription. Some enzymes act on other proteins to add or remove chemical groups in a process known as posttranslational modification. About 4,000 reactions are known to be catalysed by enzymes. The rate acceleration conferred by enzymatic catalysis is often enormous—as much as 1017-fold increase in rate over the uncatalysed reaction in the case of orotate decarboxylase (78 million years without the enzyme, 18 milliseconds with the enzyme). The molecules bound and acted upon by enzymes are called substrates. Although enzymes can consist of hundreds of amino acids, it is usually only a small fraction of the residues that come in contact with the substrate, and an even smaller fraction—three to four residues on average—that are directly involved in catalysis. The region of the enzyme that binds the substrate and contains the catalytic residues is known as the active site. Dirigent proteins are members of a class of proteins that dictate the stereochemistry of a compound synthesized by other enzymes.
=== Bethlem myopathy 2 === (Collagen XII gene) See Bethlem myopathy 2 Clinical synopsis on OMIM: 616471 In Bethlem myopathy 2, there is phenotypic variability. In one family, the only notable finding on T1-weighted MR images (used to detect fatty infiltration) was atrophy of the rectus femoris muscles of the thigh, with the degree of atrophy matching the severity of the disease, but no fatty infiltration. In another family, only the more severely affected older patient showed significant abnormality, by having symmetrical fatty atrophy of the femoral quadriceps of the thigh, the adductor and medial gastrocnemius muscles of the calf; as well as asymmetrical fatty atrophy of the adductor longus of the thigh. No muscle hypertrophy was reported and the muscles of the patients without fatty atrophy appeared normal. Bethlem myopathy 2 also differs by including the possibility of scapula winging, pectus excavatum, stooped posture, kyphosis (hunchback), micrognathia, retrognathia, and a high-arched palate. Childhood muscle weakness improves in teen years, but muscle weakness returns by the third decade of life.
The most common type of mineral tanning is chrome tanning, responsible for 85-90% of modern leather making. Chromium(III) sulfate ([Cr(H2O)6]2(SO4)3) has long been regarded as the most efficient and effective tanning agent. Chromium(III) compounds of the sort used in tanning are significantly less toxic than hexavalent chromium, although the latter arises in inadequate waste treatment. Chromium(III) sulfate dissolves to give the hexaaquachromium(III) cation, [Cr(H2O)6]3+, which at higher pH undergoes processes called olation to give polychromium(III) compounds that are active in tanning, being the cross-linking of the collagen subunits. The chemistry of [Cr(H2O)6]3+ is more complex in the tanning bath rather than in water due to the presence of a variety of ligands. Some ligands include the sulfate anion, the collagen's carboxyl groups, amine groups from the side chains of the amino acids, and masking agents. Masking agents are carboxylic acids, such as acetic acid, used to suppress formation of polychromium(III) chains. Masking agents allow the tanner to further increase the pH to increase collagen's reactivity without inhibiting the penetration of the chromium(III) complexes. Collagen is characterized by a high content of glycine, proline, and hydroxyproline, usually in the repeat -gly-pro-hypro-gly-. These residues give rise to collagen's helical structure. Collagen's high content of hydroxyproline allows cross-linking by hydrogen bonding within the helical structure. Ionized carboxyl groups (RCO2−) are formed by the action of hydroxide.
Interestingly, most of these mutations lead to exon skipping, and produce a shorter polypeptide, in which the Gly-Xaa-Yaa triplets stay in frame and there are no premature termination codons. Although vEDS is typically inherited in an autosomal-dominant manner, rare individuals with biallelic (homozygous or compound-heterozygous) COL3A1 variants – frequently null alleles – have an autosomal-recessive form of the disorder. The functional consequences of COL3A1 mutations can be studied in a cell culture system. A small punch biopsy of skin is obtained from the patient and used to start the culture of skin fibroblasts which express type III collagen. The type III collagen protein synthesized by these cells can be studied for its thermal stability. In other words, the collagens can be subjected to a short digestion by proteinases called trypsin and chymotrypsin at increasing temperatures. Intact type III collagen molecules, which have formed a stable triple helix, can withstand such treatment till about 41 °C, whereas molecules with mutations that lead to glycine substitutions fall apart at a much lower temperature. It is difficult to predict the clinical severity based on the type and location of COL3A1 mutations. Another important clinical implication is that several studies have reported on mosaicism. This refers to a situation where one of the parents carries the mutation in some, but not all of her or his cells, and appears phenotypically healthy, but has more than one affected offspring.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.